196 related articles for article (PubMed ID: 7730668)
1. The humanized severe combined immunodeficient mouse as a model for primary human humoral response against HIV1 peptides.
Chargui J; Dye D; Blomberg J; Desgranges C; Touraine JL
J Immunol Methods; 1995 Apr; 181(1):91-100. PubMed ID: 7730668
[TBL] [Abstract][Full Text] [Related]
2. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
[TBL] [Abstract][Full Text] [Related]
3. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.
Parren PW; Ditzel HJ; Gulizia RJ; Binley JM; Barbas CF; Burton DR; Mosier DE
AIDS; 1995 Jun; 9(6):F1-6. PubMed ID: 7662189
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 infection of neonatal severe combined immunodeficient mice xenografted with human cord blood cells.
Reinhardt B; Torbett BE; Gulizia RJ; Reinhardt PP; Spector SA; Mosier DE
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):131-41. PubMed ID: 8198867
[TBL] [Abstract][Full Text] [Related]
5. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
Devito C; Zuber B; Schröder U; Benthin R; Okuda K; Broliden K; Wahren B; Hinkula J
J Immunol; 2004 Dec; 173(11):7078-89. PubMed ID: 15557206
[TBL] [Abstract][Full Text] [Related]
6. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1.
Marusic C; Rizza P; Lattanzi L; Mancini C; Spada M; Belardelli F; Benvenuto E; Capone I
J Virol; 2001 Sep; 75(18):8434-9. PubMed ID: 11507188
[TBL] [Abstract][Full Text] [Related]
7. Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant.
Andrus L; Prince AM; Bernal I; McCormack P; Lee DH; Gorny MK; Zolla-Pazner S
J Infect Dis; 1998 Apr; 177(4):889-97. PubMed ID: 9534960
[TBL] [Abstract][Full Text] [Related]
8. Primary human immune response to Neisseria meningitidis serogroup C in interleukin-12-treated severe combined immunodeficient mice engrafted with human peripheral blood lymphocytes.
Westerink MA; Metzger DW; Hutchins WA; Adkins AR; Holder PF; Pais LB; Gheesling LL; Carlone GM
J Infect Dis; 1997 Jan; 175(1):84-90. PubMed ID: 8985200
[TBL] [Abstract][Full Text] [Related]
9. Primary human immunodeficiency virus type 1 viremia and central nervous system invasion in a novel hu-PBL-immunodeficient mouse strain.
Koyanagi Y; Tanaka Y; Kira J; Ito M; Hioki K; Misawa N; Kawano Y; Yamasaki K; Tanaka R; Suzuki Y; Ueyama Y; Terada E; Tanaka T; Miyasaka M; Kobayashi T; Kumazawa Y; Yamamoto N
J Virol; 1997 Mar; 71(3):2417-24. PubMed ID: 9032379
[TBL] [Abstract][Full Text] [Related]
10. Long term substitution and specific immune responses after transfer of bovine peripheral blood lymphocytes into severe combined immunodeficient mice.
Hölscher C; Hasch G; Joswig N; Stauffer U; Müller U; Mossmann H
Vet Immunol Immunopathol; 1999 Sep; 70(1-2):67-83. PubMed ID: 10507288
[TBL] [Abstract][Full Text] [Related]
11. T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: in vivo effects of HIV on highly activated human immune cells.
Rizza P; Santini SM; Logozzi MA; Lapenta C; Sestili P; Gherardi G; Lande R; Spada M; Parlato S; Belardelli F; Fais S
J Virol; 1996 Nov; 70(11):7958-64. PubMed ID: 8892919
[TBL] [Abstract][Full Text] [Related]
12. The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapy.
Boyle MJ; Connors M; Flanigan ME; Geiger SP; Ford H; Baseler M; Adelsberger J; Davey RT; Lane HC
J Immunol; 1995 Jun; 154(12):6612-23. PubMed ID: 7759895
[TBL] [Abstract][Full Text] [Related]
13. Human Ig production and isotype switching in severe combined immunodeficient-human mice.
Vandekerckhove BA; Jones D; Punnonen J; Schols D; Lin HC; Duncan B; Bacchetta R; de Vries JE; Roncarolo MG
J Immunol; 1993 Jul; 151(1):128-37. PubMed ID: 8326122
[TBL] [Abstract][Full Text] [Related]
14. Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice.
Tournoy KG; Depraetere S; Pauwels RA; Leroux-Roels GG
Clin Exp Immunol; 2000 Jan; 119(1):231-9. PubMed ID: 10606988
[TBL] [Abstract][Full Text] [Related]
15. Dose-dependent systemic human immunodeficiency virus infection of SCID-hu mice after intraperitoneal virus injection.
Grandadam M; Cesbron JY; Candotti D; Vinatier D; Pauchard M; Capron A; Debré P; Huraux JM; Autran B; Agut H
Res Virol; 1995; 146(2):101-12. PubMed ID: 7638434
[TBL] [Abstract][Full Text] [Related]
16. Generation of primary antigen-specific human cytotoxic T lymphocytes in human/mouse radiation chimera.
Segall H; Lubin I; Marcus H; Canaan A; Reisner Y
Blood; 1996 Jul; 88(2):721-30. PubMed ID: 8695821
[TBL] [Abstract][Full Text] [Related]
17. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120.
Safrit JT; Fung MS; Andrews CA; Braun DG; Sun WN; Chang TW; Koup RA
AIDS; 1993 Jan; 7(1):15-21. PubMed ID: 7680205
[TBL] [Abstract][Full Text] [Related]
18. Engraftment of human peripheral blood leukocytes into severe combined immunodeficient mice results in the long term and dynamic production of human xenoreactive antibodies.
Williams SS; Umemoto T; Kida H; Repasky EA; Bankert RB
J Immunol; 1992 Oct; 149(8):2830-6. PubMed ID: 1401915
[TBL] [Abstract][Full Text] [Related]
19. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization.
Durrani Z; McInerney TL; McLain L; Jones T; Bellaby T; Brennan FR; Dimmock NJ
J Immunol Methods; 1998 Nov; 220(1-2):93-103. PubMed ID: 9839930
[TBL] [Abstract][Full Text] [Related]
20. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
Neurath AR; Strick N; Lee ES
J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
